Terbutaline and the Prevention of Nocturnal Hypoglycemia in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Bedtime administration of 5.0 mg of the β2-adrenergic agonist terbutaline prevents nocturnal hypoglycemia but causes morning hyperglycemia in type 1 diabetes. We tested the hypothesis that 2.5 mg terbutaline prevents nocturnal hypoglycemia without causing morning hyperglycemia. RESEARCH DESIGN AND METHODS—This was a randomized double-blind crossover pilot study (placebo, 2.5 mg terbutaline, and 5.0 mg terbutaline) in 15 patients with type 1 diabetes. RESULTS—Mean ± SE nadir nocturnal plasma glucose concentrations were 87 ± 14 mg/dl following placebo, 100 ± 14 mg/dl following 2.5 mg terbutaline, and 122 ± 13 mg/dl following 5.0 mg terbutaline (P < 0.05 vs. placebo). Nadir levels were <50 mg/dl in 5, 2, and 0 patients (P < 0.05 vs. placebo), respectively. Morning levels were 113 ± 18, 127 ± 17, and 183 ± 19 mg/dl (P < 0.02 vs. placebo), respectively. CONCLUSIONS—Terbutaline may be shown to be effective and safe in the prevention of nocturnal hypoglycemia in type 1 diabetes in a suitably powered randomized controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Diverse causes of hypoglycemia-associated autonomic failure in diabetes.
Cryer, P. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031354 · Cited by 411 · cited 1×
“3 atrogenic hypoglycemia is the limiting factor in the glycemic management of diabetes (1).”
BackgroundSelf-citationDefective awakening response to nocturnal hypoglycemia in patients with type 1 diabetes mellitus
Schultes, B., Jauch-Chara, K., Gais, S., Hallschmid, M., Reiprich, E., Kern, W., Oltmanns, K. M., Peters, A., Fehm, H. L., & Born, J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040069 · Cited by 100 · cited 1×
“Sympathoadrenal responses to hypoglycemia are reduced further during sleep (5,6) and, probably because of their markedly reduced sympathoadrenal responses, patients with type 1 diabetes are substantially less likely to be awakened by hypoglycemia than nondiabetic individuals (6,7).”
BackgroundNocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments
Raju, B., Arbelaez, A. M., Breckenridge, S. M., & Cryer, P. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2798 · Cited by 93
Self-citation
Cited by
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
“Those include bedtime oral administration of the epinephrine simulating β2-adrenergic agonist terbutaline [6,53] and overnight glucagon infusion.”
BackgroundSelf-citation(2011) · PubMed · Cited by 187
Impaired Awareness of Hypoglycaemia
Frier, B. M. (2007) · Hypoglycaemia in Clinical Diabetes · doi:10.1002/9780470516270.ch7 · Cited by 22
Potential approaches to prevent hypoglycemia-associated autonomic failure
Lontchi-Yimagou, E., You, J. Y., Carey, M., Gabriely, I., Shamoon, H., & Hawkins, M. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000582 · Cited by 12
Metadata
- Authors
- Cooperberg, B. A., Breckenridge, S. M., Arbelaez, A. M., & Cryer, P. E.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-12-01
- Volume
- 31
- Issue
- 12
- Pages
- 2271-2272
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2151231069
- Cited by
- 18
- References
- 4
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.